Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)

Journal of Clinical Psychiatry

Volumn 67, Issue 5, 2006, Pages 831-832

  Kane, John M ^a,b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CLOZAPINE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; FUNCTIONAL DISEASE; HUMAN; INTERVENTION STUDY; MENTAL HEALTH; NON PROFIT ORGANIZATION; NOTE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 33745383138     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v67n0519     Document Type: Note

References (10)

1. Lieberman JA. J Clin Psychiatry 1999;60(suppl 12):9-12
2. Stroup TS, McEvoy JP, Swartz MS, et al. Schizophr Bull 2003;29:15-31
3. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. N Engl J Med 2005;353:1209-1223
4. Robinson DG, Woerner MG, Delman HM, et al. Schizophrenia Bull 2005;31:705-722
5. Davis JM, Chen N. Eur Psychiatry 2005;20:7-14
6. Kane JM, Rifkin A, Woerner M, et al. Arch Gen Psychiatry 1983;40:893-896
7. Heres S, Davis J, Maino K, et al. Am J Psychiatry 2006;163:185-194
8. Lehman AF, Lieverman JA, Dixon LB, et al. American Psychiatric Association. Am J Psychiatry 2004;161(suppl 2):1-56
9. Kane JM, Leucht S, Carpenter D, et al. J Clin Psychiatry 2003;64(suppl 12):5-19
10. Lieberman JA, Stroup TS, Davis SM. N Engl J Med 2006;354:298-300